
Geoffrey Y. Ku, MD, explains the latest developments with bispecific antibodies in patients with gastric and gastroesophageal junction cancers.

Geoffrey Y. Ku, MD, explains the latest developments with bispecific antibodies in patients with gastric and gastroesophageal junction cancers.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Manojkumar Bupathi, MD, MS, discusses the key trials that have made a splash in prostate cancer in the last year.

Purpose-built, decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just a last resort.

Geoffrey Y. Ku, MD, highlights ongoing advances in gastric/GEJ treatment.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

Gavin Wright, MBBS, discusses how the tumor-targeted imaging agent abenacianine helped surgeons locate hard-to-find tumors in the phase 2b VISUALIZE trial.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

Ryan Funk, MD, explains how 2026 CMS coding changes and commercial payer contracts are straining radiation oncology practices, threatening rural and freestanding centers and patient access to care.

Dr Shubham Pant outlines what's next for daraxonrasib in pancreatic cancer, including the RASolute 303 and RASolute 304 trials.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T-cell therapies move earlier.

Surbhi Sidana, MD, discusses the ongoing trials that could expand the use of iberdomide into various combinations and settings in patients with multiple myeloma.

System barriers like interoperability gaps, prior authorization delays, and reimbursement pressures intensify oncology physician burnout, disrupting care coordination and straining community practices.

Shubham Pant, MD, MBBS, reviews the common adverse effects of daraxonrasib and the prophylactic strategies his team uses to manage them in pancreatic cancer.

Surbhi Sidana, MD, discusses the key aspects of iberdomide that make the CELMoD's FDA approval so significant for multiple myeloma treatment.

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and AI-powered documentation.

Actionable strategies curb oncologist burnout by easing admin workload, enabling true PTO disconnect, strengthening leadership communication, and boosting self-care support.

A gynecologic oncologist unpacks shifting cancer trends, HRD and germline testing, screening pitfalls, and where new treatments are headed.

Clark Chen, MD, discusses where tile-based radiation therapy fits within the broader glioblastoma treatment regimen and where the approach may be headed next.

Spot physician burnout early by recognizing emotional exhaustion, rising cynicism, and slipping effectiveness—before staff turnover and patient care suffer.

Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and neglected self-care—pointing to systemic fixes.

Adam Cuker, MD, MS, and Amit R. Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia.

Surbhi Sidana, MD, discusses the versatility of iberdomide and the approved Iber-Dd regimen in relapsed multiple myeloma.

In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with 93% of patients starting chemoradiation on schedule.

Oncology leaders weigh how to scale trustworthy AI platforms, align governance, and integrate care-research workflows for real-world adoption.

AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond academic centers and reducing barriers such as distance and logistics.

In an interview, Surbhi Sidana, MD, explores the significance of iberdomide's FDA approval and how this agent fits into the growing array of novel multiple myeloma therapies.

Agentic AI speeds oncology trial screening by synthesizing records and ranking candidates, while clinicians keep final eligibility and consent decisions.

Laila Alkhouli, MD, discusses the importance of early detection of chronic graft-vs-host-disease and why standardizing screening is crucial.